Aim: We investigated the effect of alogliptin and gliclazide on endothelial progenitor cells (EPCs) in type 2 diabetes.
Methods: Eighty patients with type 2 diabetes and HbA1c between 7.5% and 8.5% were randomized to receive either alogliptin (25 mg/daily) or gliclazide extended-release (30 mg/daily for HbA1c 7.5-8.0% and 60 mg/daily for HbA1c 8.0-8.5%) in combination with metformin for 4 months. At baseline and 4 months, clinical and laboratory parameters of EPCs were determined.
Results: After 4 months of treatment, alogliptin and gliclazide resulted in a similar significant reduction in HbA1c (%) (8.0±0.3 vs. 7.1±0.2, and 8.0±0.3 vs. 7.0±0.2, respectively; P<0.05) and a similar and significant increase in EPC count (cells/10 WBC) (CD45CD133KDR : 2.2±1.2 vs. 3.7±1.6, CD45CD34KDR: 3.3±18 vs. 4.9±1.8; P<0.05 for alogliptin; CD45CD133KDR: 2.3±1.3 vs. 36±1.5, CD45CD34KDR: 3.1±1.3 vs. 46±1.7; P<0.05 for gliclazide).
Conclusions: Both alogliptin and gliclazide demonstrated a beneficial effect in increasing EPCs in poorly controlled type 2 diabetes. As alogliptin and gliclazide exhibit different mechanisms of action, the observed increase in EPCs seems to be due to their glucose-lowering effect.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0043-122383 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacologic Heterogeneity and Risk of Severe Hypoglycemia with Concomitant Use of Sulfonylureas and DPP-4 Inhibitors: Population-Based Cohort Study.
Clin Pharmacol Ther
September 2023
Department of Medicine, McGill University, Montreal, Quebec, Canada.
Dipeptidyl peptidase-4 inhibitors (DPP-4i) interact with sulfonylureas to increase their risk of hypoglycemia. Our population-based study assessed whether intraclass pharmacologic heterogeneity among sulfonylureas (long- vs. short-acting) and DPP-4i (peptidomimetic vs.
View Article and Find Full Text PDFEffects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.
Front Endocrinol (Lausanne)
February 2022
Affiliated Dongguan Hospital, Southern Medical University, Dongguan, Guangdong, China.
Purpose: Available data on the effects of anti-diabetic drugs on fracture risk are contradictory. Therefore, our study aimed to analyze all available data on the effects of anti-diabetic drugs on fracture risk in type 2 diabetes mellitus (T2DM) patients.
Methods: Embase, Medline, ClinicalTrials.
Rare case of diabetic neuropathic cachexia along with diabetic amyotrophy.
BMJ Case Rep
May 2021
Acute Medical Unit, Southend Hospital, Westcliff-on-Sea, Essex, UK.
A 65-year-old patient with background of alcohol excess and previous gunshot wounds was admitted with significant weight loss, leg cramps, dizziness and lethargy for the last 3 months. He was diagnosed with type 2 diabetes mellitus in July 2020 and was started on Metformin and Gliclazide by his in July; he was later commenced on alogliptin and empaglaflozin by diabetes specialist nurse in early August. He also had generalised muscle wasting, dorsal guttering in both hands and was cachectic when he presented to hospital.
View Article and Find Full Text PDFAlogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients.
Exp Clin Endocrinol Diabetes
April 2019
San Raffaele Hospital, Faculty of Medicine, Milano, Italy.
Aim: We investigated the effect of alogliptin and gliclazide on endothelial progenitor cells (EPCs) in type 2 diabetes.
Methods: Eighty patients with type 2 diabetes and HbA1c between 7.5% and 8.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!